TrialBreast cancer research and treatment2014

Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.

Vakaramoko Diaby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.